SEC Filing | TELA Bio, Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Talmo Paul

(Last)

(First)

(Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN

19355

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2022

3. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Strategic Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock⁽¹⁾	30,470	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	02/24/2027	Common Stock	4,050	5.93	D
Stock Option (Right to Buy)	⁽³⁾	02/24/2027	Common Stock	10,125	5.93	D
Stock Option (Right to Buy)	⁽⁴⁾	02/24/2027	Common Stock	10,125	5.93	D
Stock Option (Right to Buy	⁽⁵⁾	02/28/2028	Common Stock	9,801	5.93	D
Stock Option (Right to Buy	⁽⁶⁾	11/07/2029	Common Stock	70,879	13	D
Stock Option (Right to Buy	⁽⁷⁾	02/24/2031	Common Stock	21,500	16.99	D
Warrants (Right to Buy)	11/13/2019	01/18/2027	Common Stock	204	28.65	D

Explanation of Responses:

1. Common stock includes 11,800 restricted stock units and 2,510 restricted stock units that will vest in four equal annual installments beginning on February 24, 2022 and March 31, 2022, respectively, each subject to the Reporting Person's continued service through the applicable vesting dates.

2. The option vested 50% on February 24, 2017 and 12.5% on February 24, 2018, with the remaining 37.5% having vested in equal monthly installments on the last day of each of the 36 calendar months immediately following February 2018.

3. The option vested immediately upon TELA Bio, Inc. (the "Company") achieving cumulative net sales exceeding $10.0 million.

4. The option vested immediately upon the Company achieving cumulative net sales exceeding $30.0 million.

5. The option vested 25% on February 28, 2019, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

6. The option vested 25% on November 7, 2020, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

7. The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

	/s/ Megan Smeykal, Attorney-in-fact	01/07/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.